Macitentan D4 is the tetra-deuterated form of Macitentan (ACT-064992;
ACT064992; Opsumit) which is a dual antagonist of ETA/ETB endothelin (ET) receptor approved for the treatment of pulmonary arterial hypertension
(PAH).